Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
12.08. | Tela Bio reiterates $85M-$88M 2025 revenue target as international expansion accelerates | 1 | Seeking Alpha | ||
11.08. | TELA Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
11.08. | TELA Bio GAAP EPS of -$0.22, revenue of $20.2M | 4 | Seeking Alpha | ||
11.08. | TELA Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
11.08. | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
11.08. | TELA Bio, Inc.: TELA Bio Reports Second Quarter 2025 Financial Results | 109 | GlobeNewswire (Europe) | MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
TELA BIO Aktie jetzt für 0€ handeln | |||||
08.08. | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 113 | GlobeNewswire (Europe) | MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
21.07. | TELA Bio, Inc.: TELA Bio to Announce Second Quarter 2025 Financial Results | 2 | GlobeNewswire (USA) | ||
06.06. | TELA Bio, Inc.: TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 153 | GlobeNewswire (Europe) | MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
03.06. | TELA Bio, Inc.: TELA Bio Announces European Commercial Launch of OviTex Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair | 111 | GlobeNewswire (Europe) | MALVERN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
02.06. | TELA Bio ernennt Jeffrey Blizard zum neuen Präsidenten | 2 | Investing.com Deutsch | ||
02.06. | TELA Bio, Inc.: TELA Bio Appoints Jeffrey Blizard as President | 150 | GlobeNewswire (Europe) | MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
30.05. | TELA Bio, Inc. - 8-K, Current Report | 6 | SEC Filings | ||
20.05. | Piper Sandler maintains TELA Bio stock at Neutral with $2 target | 2 | Investing.com | ||
09.05. | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 115 | GlobeNewswire (Europe) | MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
09.05. | TELA Bio GAAP EPS of -$0.25 misses by $0.05, revenue of $18.5M beats by $1.15M | 2 | Seeking Alpha | ||
08.05. | TELA Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
17.04. | TELA Bio, Inc.: TELA Bio to Announce First Quarter 2025 Financial Results | 2 | GlobeNewswire (USA) | ||
09.04. | Canaccord maintains TELA Bio stock with $7 target post-challenges | 1 | Investing.com | ||
31.03. | TELA Bio introduces larger sizes for soft tissue reconstruction | 1 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MODERNA | 20,705 | +0,58 % | Moderna, Inc.: Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2 | CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 15,670 | +0,61 % | S&P Dow Jones Indices: Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600 | NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE: ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and... ► Artikel lesen | |
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,151 | +3,12 % | PacBio Board Independent Investigation Concludes Allegations Unsubstantiated | MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the "Special Committee") has concluded its independent... ► Artikel lesen | |
MYRIAD GENETICS | 5,550 | +1,83 % | ANGLE plc: ANGLE Announces Collaboration with Myriad Genetics | Assessment of feasibility for use of Parsortix derived circulating tumour cell (CTC) DNA with Myriad Genetics' existing tissue-based diagnostic test GUILDFORD, SURREY / ACCESS Newswire / August 20,... ► Artikel lesen | |
PHIO PHARMACEUTICALS | 2,000 | +1,01 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update | Clinical trial advances for INSTASYL siRNA lead product candidate PH-7625th cohort enrolling patients in on-going clinical studyKing of Prussia, Pennsylvania--(Newsfile Corp. - August 14, 2025) - Phio... ► Artikel lesen | |
CYTOMX THERAPEUTICS | 1,701 | -2,69 % | CytomX: Wie geht's hier jetzt weiter? | Die Immuntherapie gegen Krebs entwickelt sich stetig weiter, und CytomX Therapeutics gehört zu den Unternehmen, die mit innovativen Ansätzen neue Maßstäbe setzen wollen. Die sogenannte "Probody"-Technologie... ► Artikel lesen | |
VIR BIOTECHNOLOGY | 4,950 | -1,79 % | Vir Biotechnology-Aktie springt nach Hochstufung deutlich an | Die Aktien von Vir Biotechnology legten am Mittwoch zweistellig zu. Auslöser war eine Aufstufung durch BofA Securities, die das Papier des US-Biotech-Unternehmens von "Neutral" auf "Kaufen" anhob und... ► Artikel lesen | |
RAPT THERAPEUTICS | 9,500 | 0,00 % | XFRA 0RA0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
TC BIOPHARM | 0,825 | 0,00 % | TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient | First patient in Cohort B achieved CR after 2nd dose of TCB008
EDINBURGH, Scotland, June 11, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC (NASDAQ: TCBP)... ► Artikel lesen | |
QIAGEN | 40,590 | +2,22 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten Staaten an | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Anleiheemission
QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 58,58 | +0,72 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
EVOTEC | 6,072 | +1,20 % | Die Blaupause für KI-Medikamentenentwicklung: So nutzen Evotec, NetraMark Holdings und BioNTech die neuen Möglichkeiten | Die Pharmabranche befindet sich mitten in einer Revolution. Künstliche Intelligenz verkürzt die Wirkstoffentwicklung von Jahren auf Monate und steigert die Trefferquote dramatisch. Datengetriebene Prognosen... ► Artikel lesen | |
BIONTECH | 86,45 | +0,99 % | Paukenschlag beim Übernahmekandidaten! 100 %-Aktie BioNxt Solutions lässt BioNTech und Co. hinter sich! | Die Aktie von BioNxt ist endlich angesprungen. Anfang Juli hatten wir zuletzt auf die Chancen des kanadisch-deutschen Biowissenschaftsunternehmens hingewiesen. Seitdem ist die Aktie um fast 100 % gestiegen... ► Artikel lesen | |
IMMUNOVANT | 14,690 | -0,88 % | Immunovant, Inc. - 8-K, Current Report | ||
ARS PHARMACEUTICALS | 11,610 | -9,72 % | ARS Pharma drops 9% as Lupin files application for generic neffy |